CINCINNATI--(BUSINESS WIRE)--Camargo Pharmaceutical Services, the most experienced global strategist in the drug development industry specializing in the 505(b)(2) approval pathway, has appointed Jason Moore as vice president of global program management.
Moore will be responsible for enhancing Camargo’s project management process from proposals through project completion, which will be key to helping Camargo create the capacity to meet increasing client demand, according to Ken Phelps, Camargo president and CEO. “Camargo has achieved significant growth over the past few years, and leaders like Jason are both the sustainers and drivers of that growth and the reason we’ll be able to build on it in the future,” said Phelps.
Moore brings more than 20 years of global drug development experience to Camargo, including specialized expertise ranging from enterprise project management and portfolio optimization to clinical studies and regulatory submissions, with extensive knowledge of the laws, regulations and guidances governing global drug development.
Before joining Camargo, Moore was vice president at PLx Pharma for seven years, where he led all regulatory affairs functions and product submissions for five active investigational new drugs and one approved new drug application. He also held positions of increasing responsibility at organizations including BioHouston, Introgen and Agenus.
“Jason is a terrific addition to the team and we’re looking forward to his contributions to our clinical and regulatory service delivery,” said Jim Beach, Camargo chief operating officer. “Our clients’ needs are only becoming more complex and we need to ensure that our program management capabilities are able to meet these demands, both for today and going forward. Jason’s project management acumen will make sure Camargo can accommodate clients in any stage of their growth cycle and fulfill evolving needs seamlessly, efficiently and completely.”
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is the most experienced global strategist providing comprehensive drug development services specialized for the 505(b)(2) approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory and commercial viability of product development opportunities, Camargo systematically builds and executes robust development plans that align with business strategies and ensure FDA buy-in every step of the way. Routinely holding three to six pre-IND meetings a month, Camargo works with product developers across more than 25 countries. Connect with Camargo on LinkedIn, read the company blog and visit camargopharma.com for more information.